| 货号 | 13875-10mg |
| 描述 | Valganciclovir is the valyl ester prodrug of ganciclovir (Item No. 13853), an antiviral agent used for the treatment of HIV associated retinitis and for the prevention of post transplant cytomegalovirus (CMV) infections.1,2,3,4 Upon oral administration, intestinal and hepatic esterases rapidly convert valganciclovir to ganciclovir, which can inhibit viral DNA synthesis (IC50 = 0.95 μM) by targeting the CMV polymerase.5 |
| 别名 | Ro 107-9070/194;Valcyte®; |
| 供应商 | Cayman |
| 应用文献 | |
| 1.Pescovitz, M.D. Valganciclovir: Recent progress. American Journal of Transplantation 10(6), 1359-1364 (2010). 2.Paltiel, A.D.,Goldie, S.J.,Losina, E., et al. Preevaluation of clinical trial data: The case of preemptive cytomegalovirus therapy in patients with human immunodeficiency virus. Clinical Infectious Diseases 32(5), 782-793 (2001). 3.Paya, C.V.,Wilson, J.A.,Espy, M.J., et al. Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: A randomized, placebo-controlled trial. Journal of Infectious Diseases 185(7), 854-860 (2002). 4.Sun, H.Y.,Wagener, M.M. and Singh, N. Prevention of posttransplant cytomegalovirus disease and related outcomes with valganciclovir: A systematic review. American Journal of Transplantation 8(10), 2111-2118 (2008). 5.Biron, K.K.,Harvey, R.J.,Chamberlain, S.C., et al. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrobial Agents and Chemotherapy 46(8), 2365-2372 (2002). | |
| 运输条件 | Wet ice in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥95% |
| 计算分子量 | 390.8 |
| 分子式 | C14H22N6O5 • HCl |
| CAS号 | 175865-59-5 |
| 稳定性 | ≥ 2 years |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |